Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved symbols : Jazz save search
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.07%
H: 1.1%
C: -0.34%
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.72%
enrylaze approval treatment pharmaceuticals leukemia
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Published: 2023-09-21 (Crawled : 22:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.72%
enrylaze approval treatment pharmaceuticals leukemia
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Published: 2022-11-18 (Crawled : 00:20) - biospace.com/
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: 0.85%
H: 1.29%
C: 0.56%
rylaze fda pharmaceuticals approval
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
Published: 2021-08-12 (Crawled : 19:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.14%
H: 1.0%
C: -2.26%
fda fda approval approval sodium oxybate
GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
Published: 2021-08-10 (Crawled : 09:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.32%
H: 0.12%
C: -3.88%
treatment sclerosis approval
National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia
Published: 2021-07-22 (Crawled : 21:00) - biospace.com/
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: -1.69%
cancer leukemia
Health Canada Approves Vyxeos the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML)
Published: 2021-07-07 (Crawled : 22:00) - biospace.com/
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: 0.31%
H: 0.99%
C: 0.28%
myeloid leukemia risk therapy leukemia acute myeloid leukemia aml
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Published: 2021-07-01 (Crawled : 01:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: 1.71%
H: 1.13%
C: 0.28%
treatment fda fda approval leukemia approval
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
Published: 2021-04-23 (Crawled : 21:00) - globenewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
| Email alert
Add to watchlist
acquisition approval
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
Published: 2021-03-30 (Crawled : 23:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: 0.37%
H: 0.84%
C: -1.63%
treatment fda myeloid leukemia fda approval leukemia approval acute myeloid leukemia
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.